LYMPHOID NEOPLASIA An RCOR1 loss – associated gene expression signature identi fi es a prognostically signi fi cant DLBCL subgroup

to treatment failure. Systematic integration of high-resolution genotyping arrays and RNA sequencing data revealed novel deletions in RCOR1 to be associated with unfavorable progression-free survival ( P 5 .001). Integration of expression data from the clinical sam-pleswithdatafrom RCOR1 knockdownsinthelymphomacelllinesKM-H2andRajiyielded an RCOR1 loss–associatedgenesignaturecomprising233genes.Thissignatureidentified a subgroup of patients with unfavorable overall survival ( P 5 .023). The prognostic significance of the 233-gene signature for overall survival was reproduced in an independent cohortcomprising195R-CHOP-treatedpatients( P 5 .039).Additionally,wediscoveredthat within the International Prognostic Index low-risk group, the gene signature provides addi-tionalprognosticvaluethatwasindependentofthecell-of-originphenotype.Wepresentanovelandreproduciblemolecularsubgroupof DLBCLthatimpactsrisk-stratificationofR-CHOP-treatedDLBCLpatientsandrevealsapossiblenewavenuefortherapeuticintervention strategies. (

[1]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[2]  A. Bashashati,et al.  DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.

[3]  Stefano Monti,et al.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. , 2012, Cancer cell.

[4]  Seungtai Yoon,et al.  A tumour suppressor network relying on the polyamine–hypusine axis , 2012, Nature.

[5]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[6]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[7]  J. Friedberg.  Relapsed/refractory diffuse large B-cell lymphoma. , 2011, Hematology. American Society of Hematology. Education Program.

[8]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[9]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[10]  S. Kulkarni,et al.  High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy. , 2011, Cancer genetics.

[11]  Christian Steidl,et al.  Cooperative epigenetic modulation by cancer amplicon genes. , 2010, Cancer cell.

[12]  Oliver Sieber,et al.  A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data , 2010, Genome Biology.

[13]  T. Molina,et al.  Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. , 2010, Blood.

[14]  L. Stein,et al.  A human functional protein interaction network and its application to cancer data analysis , 2010, Genome Biology.

[15]  Serban Nacu,et al.  Fast and SNP-tolerant detection of complex variants and splicing in short reads , 2010, Bioinform..

[16]  H. Drexler,et al.  NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells , 2009, BMC Cancer.

[17]  J. Carpten,et al.  Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. , 2009, Cancer research.

[18]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[19]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[20]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[21]  Joseph T. Glessner,et al.  PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. , 2007, Genome research.

[22]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[23]  Gouri Nanjangud,et al.  Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. , 2006, Blood.

[24]  Stefano Monti,et al.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.

[25]  L. Staudt,et al.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. , 2005, Blood.

[26]  H. Tagawa,et al.  Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.

[27]  H. Tagawa,et al.  Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma , 2004, Oncogene.

[28]  E. Harhaj,et al.  Regulation of the NF-κB-inducing Kinase by Tumor Necrosis Factor Receptor-associated Factor 3-induced Degradation* , 2004, Journal of Biological Chemistry.

[29]  G. Dewald,et al.  A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. , 2002, The American journal of pathology.

[30]  R. Shiekhattar,et al.  A core–BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[32]  P. Brehm,et al.  Regulation of Neuronal Traits by a Novel Transcriptional Complex , 2001, Neuron.

[33]  S. Schreiber,et al.  CoREST is an integral component of the CoREST- human histone deacetylase complex. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[35]  Raymond Dingledine,et al.  Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes , 1999, Nature Neuroscience.

[36]  Gail Mandel,et al.  REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons , 1995, Cell.

[37]  D J Anderson,et al.  The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes , 1995, Science.